NeuExcell Therapeutics is developing gene therapies to treat neurodegenerative diseases. Loss of neuronal function is a common feature of neurodegenerative diseases causing millions of patients worldwide to suffer. NeuExcell is investigating the latest biotechnologies to find effective therapies to regenerate neural tissue in damaged areas. NeuExcell’s approach is supported by the discovery of in vivo astrocyte-to-neuron (AtN) conversion using gene therapy. Taking advantage of AtN, NeuExcell has shown in animal models of Huntington’s disease and stroke that the therapy repairs neural tissues, motor function and mitigates cognitive deficits. NeuExcells third leading candidate program is in Amyotrophic Lateral Sclerosis.
Claim company profile to post jobs directly on this page and this website.